Clinical trial · Observational
Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment
Recherche de Biomarqueurs prédictifs de réponse ou de résistance Dans Les Traitements Des Cancers du Sein
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer (Triple Negative Type) | Malignant Breast Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients follow-up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast Cancer Patients at Saint-Louis Hospital
- description
- Patients with newly diagnosed or recurrent breast cancer managed at the breast surgery and senology units. Residual tumor tissue, blood, and clinical data will be collected for analysis.
- interventionNames
- Other: Patients follow-up
Primary outcomes (1)
- measure
- Number of Predictive Multimodal Biomarkers identified
- timeFrame
- Up to 10 years
- description
- Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.
Secondary outcomes (3)
- measure
- Overall Survival Analysis by Biomarker Subgroup
- timeFrame
- Up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed breast cancer * Managed at Saint-Louis Hospital * No opposition to participation in research * Affiliation to the French national health system Exclusion Criteria: * Expressed opposition to research * Legal incapacity or under legal protection * Patients under State Medical Aid (AME)
References
Publications (0)
Data not yet available